SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Sci Rep. 2022;12(1):6386.

Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy.

, , , , , , , , , , ,

제1저자 권순일 · 교신저자 김형관

소속 (4)
  1. Section of Cardiovascular Imaging, Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, Seoul National University and Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.
  2. Section of Cardiovascular Imaging, Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, Seoul National University and Seoul National University Hospital, 103 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. cardiman73@gmail.com.
  3. Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea.
  4. Department of Cardiology, Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea.

Abstract

Insufficient evidence is available comparing mortality and cause of death between general hypertrophic cardiomyopathy (HCM) and general non-HCM populations. We aimed to investigate how causes of death and mortality differ in subjects with and without HCM. Using the National Health Insurance Service database from 2009 to 2016, individuals who underwent health check-up(s) with or without a history of HCM were identified. Participants in the HCM group were matched at a 1:1 ratio with those in the non-HCM group using propensity scores calculated from the baseline covariates. Mortality rates and risks were compared between the groups. In total, 14,858 participants (7,429 each in the HCM and non-HCM groups) were followed up over a mean 4.4 ± 2.2 years (mean age, 61.0 years; male proportion, 66.8%). Compared to the non-HCM group, the HCM group showed a higher risk of all-cause and HCM-related mortality and a similar risk for non-cardiovascular mortality (hazard ratio [95% confidence interval] 1.57 [1.38-1.78], 2.71 [1.92-3.83], and 1.04 [0.88-1.23], respectively). The sensitivity analyses consistently showed that the HCM group showed higher risks of all-cause and HCM-related mortality than the non-HCM group. The female participants with HCM were associated with an increasing trend of the risks of all-cause mortality but not HCM-related mortality compared to their male counterparts (p for interaction < 0.001 and 0.185, respectively). In conclusion, compared to the non-HCM population, the general HCM population showed higher risks of both all-cause and HCM-related mortality, but had a similar risk of non-cardiovascular mortality.

© 2022. The Author(s).

Figures

Figure 1
Figure 1 The flowchart of the study design. Using the NHIS database, subjects who were diagnosed with HCM between 2009 and 2016 were selected and exactly matched at a 1:1 ratio with the non-HCM group using a propensity score. HCM hypertrophic cardiomyopathy, NHIS National Health Insurance Service.
Figure 2
Figure 2 Cumulative mortality according to the cause of death. All-cause mortality, HCM-related mortality, and other cardiovascular mortality were significantly higher in the HCM group compared with those in the non-HCM group. Mortality from non-cardiovascular causes, however, were not significantly different between the HCM and the non-HCM groups. HCM hypertrophic cardiomyopathy.
Figure 3
Figure 3 Mortality rates and risks according to the cause of death. Mortality rates, mortality risks with 95% CIs, and p-values are presented. Mortality rates were higher in the HCM group than in the non-HCM group, irrespective of the cause of death. Compared to the non-HCM group, the HCM group was associated with significantly higher risks for all-cause, HCM-related, and other cardiovascular mortality. Non-cardiovascular mortality was comparable in the HCM group versus the non-HCM group. HCM hypertrophic cardiomyopathy, CV cardiovascular, REF reference, PY person-year, HR hazard ratio, CI confidence interval.
Figure 4
Figure 4 Subgroup analyses. PY person-year, HR hazard ratio, CI confidence interval, HCM hypertrophic cardiomyopathy, REF reference.

그림 출처: PubMed Central 공개 논문 (PMC9013352)

Conflict of interest statement

H.K.K reports research grants from Johnson & Johnson, Handok Pharm, GSK, Dae-Woong Pharm, Yuhan, Hanmi, ChongKunDang Pharm, Boryung Pharm, and JW Pharm. The remaining authors have no competing interests.

그 밖의 정보
출판 형태
Journal Article
저널
Scientific reports · eISSN 2045-2322
전자 출판
2022-04-16
MeSH
Adult · Cardiomyopathy, Hypertrophic* / complications · Cause of Death · Female · Humans · Male · Middle Aged · Propensity Score · Proportional Hazards Models
참고문헌
26편